Literature DB >> 8044087

Recent developments in the drug treatment of motor neurone disease.

R W Orrell, R J Lane, R J Guiloff.   

Abstract

Mesh：

Year:  1994        PMID： 8044087      PMCID： PMC2540678          DOI： 10.1136/bmj.309.6948.140

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  17 in total

1.  A double-blind placebo-controlled trial of L-threonine in amyotrophic lateral sclerosis.

Authors:  O Blin; J Pouget; G Aubrespy; C Guelton; A Crevat; G Serratrice
Journal:  J Neurol       Date:  1992-02       Impact factor: 4.849

2.  Intrathecal thyrotropin-releasing hormone does not alter the progressive course of ALS: experience with an intrathecal drug delivery system.

Authors:  T L Munsat; J Taft; I M Jackson; P L Andres; D Hollander; L Skerry; M Ordman; D Kasdon; L Finison
Journal:  Neurology       Date:  1992-05       Impact factor: 9.910

Review 3.  Use of TRH analogues in motorneurone disease.

Authors:  R J Guiloff
Journal:  Ann N Y Acad Sci       Date:  1989       Impact factor: 5.691

Review 4.  Motoneuron survival factors: biological roles and therapeutic potential.

Authors:  C E Henderson; E Bloch-Gallego; W Camu; A Gouin; C Lemeulle; C Mettling
Journal:  Neuromuscul Disord       Date:  1993 Sep-Nov       Impact factor: 4.296

Review 5.  Excitatory amino acids as a final common pathway for neurologic disorders.

Authors:  S A Lipton; P A Rosenberg
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

6.  Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation.

Authors:  D B Drachman; V Chaudhry; D Cornblath; R W Kuncl; A Pestronk; L Clawson; E D Mellits; S Quaskey; T Quinn; A Calkins
Journal:  Ann Neurol       Date:  1994-02       Impact factor: 10.422

7.  Branched-chain amino acids in the treatment of amyotrophic lateral sclerosis.

Authors:  D Testa; T Caraceni; V Fetoni
Journal:  J Neurol       Date:  1989-12       Impact factor: 4.849

8.  Ciliary neurotrophic factor: pharmacokinetics and acute-phase response in rat.

Authors:  F Dittrich; H Thoenen; M Sendtner
Journal:  Ann Neurol       Date:  1994-02       Impact factor: 10.422

9.  A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.

Authors:  G Bensimon; L Lacomblez; V Meininger
Journal:  N Engl J Med       Date:  1994-03-03       Impact factor: 91.245

10.  Pilot trial of branched-chain aminoacids in amyotrophic lateral sclerosis.

Authors:  A Plaitakis; J Smith; J Mandeli; M D Yahr
Journal:  Lancet       Date:  1988-05-07       Impact factor: 79.321
View more
  3 in total

1.  ISIS Survey: an international study on the diagnostic process and its implications in amyotrophic lateral sclerosis.

Authors:  A Chiò
Journal:  J Neurol       Date:  1999-11       Impact factor: 4.849

Review 2.  Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis.

Authors:  H M Bryson; B Fulton; P Benfield
Journal:  Drugs       Date:  1996-10       Impact factor: 9.546

Review 3.  Familial amyotrophic lateral sclerosis/motor neurone disease (FALS): a review of current developments.

Authors:  J de Belleroche; R Orrell; A King
Journal:  J Med Genet       Date:  1995-11       Impact factor: 6.318
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.